A Randomized, Adaptive, Investigator/ Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2018
At a glance
- Drugs RG7835 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Roche
- 26 Nov 2018 Planned End Date changed from 3 Oct 2018 to 4 Dec 2018.
- 26 Nov 2018 Planned primary completion date changed from 3 Oct 2018 to 4 Dec 2018.
- 13 Sep 2018 Planned End Date changed from 21 Nov 2018 to 3 Oct 2018.